RxDoctor Payments Data

Richard Dumois, MD

Gastroenterology · Orlando, FLNPI 1417921115

Payments from drug & device makers

$17,309in general payments, 2019–2025

Across 701 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Intra-sana Laboratories$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Pfizer$917
  • plus $7K from 40 others

What the payments were for

  • Food & beverage$17,20999%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,309 in reported general payments places this provider in the 80th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$71,156
Medicare patients
256
Services billed
517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase54$183,421
SucraidSacrosidase25$159,782
ZenpepLipase/Protease/Amylase22$89,718
LinzessLinaclotide52$52,582
MotegrityPrucalopride Succinate13$9,869
ClenpiqSod Picosulf/Mag Ox/Citric Ac51$8,736
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates94$5,780
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,607
Pantoprazole Sodium240$2,594
Sucralfate19$2,234
Omeprazole136$1,873
Esomeprazole Magnesium29$1,337
Famotidine70$925
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl54$782
Dicyclomine Hcl26$643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$3,163$236,002106 claims
QOL Medical, LLCSucraid$405$159,78225 claims
Aimmune Therapeutics, Inc.Zenpep$56$89,71822 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,011$9,86913 claims
Ferring Pharmaceuticals Inc.Clenpiq$37$8,73651 claims
Braintree Laboratories, Inc.Sutab$40$2,60716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →